Skye Bioscience announced that nimacimab, its peripheral cannabinoid receptor 1 (CB1) inhibitor antibody, failed to produce significant weight loss as monotherapy in a 26-week phase 2a trial. Nimacimab alone led to an average 1.5% weight loss, not statistically outperforming placebo. However, the combination of nimacimab with semaglutide exhibited clinically meaningful additional weight loss beyond semaglutide alone, with a favorable safety profile and no neuropsychiatric concerns. These findings suggest potential for higher dosing and combination regimens in future studies.